Study Evaluating Single Ascending Doses Of ILS-920

Completed

Phase 1 Results N/A

Trial Description

This is a first-in-human study of ILS-920. This study will provide an initial assessment of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ILS-920 after administration of ascending single intravenous (IV) doses to healthy adult subjects.

Conditions

Interventions

  • ILS-920 Drug
    ARM 1: Kind: Experimental
    Label: 1
    Description: ILS-920

Trial Design

  • Allocation: Randomized
  • Masking: Double-Blind
  • Purpose: Treatment
  • Endpoint: Safety Study
  • Intervention: Single Group Assignment

Outcomes

Type Measure Time Frame Safety Issue
Primary Safety based on vital sign evaluations, 12-lead ECGs, cardiac rhythm monitoring and routine lab tests. 48 hours after study drug administration Yes
Secondary Pharmacokinetics will measure the extent and rate of Absorption, Distribution, Metabolism and Excretion of the drug in the body. 48 hours after study drug administration No

Sponsors